UK markets closed

Guardant Health, Inc. (GH)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
109.96-1.73 (-1.55%)
As of 12:44PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close111.69
Bid109.69 x 800
Ask110.11 x 1100
Day's range109.20 - 111.63
52-week range55.90 - 114.33
Avg. volume947,593
Market cap10.954B
Beta (5Y monthly)0.50
PE ratio (TTM)N/A
EPS (TTM)-1.27
Earnings date05 Nov 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est116.00
  • Investor's Business Daily Video

    Guardant Health Soars

    Oncology firm Guardant Health bounced off its 10-week moving average after a breakout from a base in September.

  • Is Guardant Health Stock a Buy?
    Motley Fool

    Is Guardant Health Stock a Buy?

    Many cancer patients undergoing treatment have impaired immune systems, so it's not a big surprise that some of them stayed away from clinic settings during the spring, when cases of COVID-19 were growing rapidly in the United States. Guardant Health (NASDAQ: GH), a company specializing in detecting cancer DNA circulating in the blood, saw a dip in clinical volume during that time, dampening results after the company more than doubled its revenue last year. Guardant's revenue comes from tests taken by seriously ill cancer patients and drug companies conducting research in new treatments, and neither of those sorts of customers are going to put off buying the company's products for long.

  • Guardant Health Announces Webcast of Third Quarter Financial Results on November 5, 2020
    Business Wire

    Guardant Health Announces Webcast of Third Quarter Financial Results on November 5, 2020

    Guardant Health, Inc. (Nasdaq: GH) today announced it will report financial results for the third quarter 2020 after market close on Thursday, November 5, 2020. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.